Honigman Advises Elucid Bioimaging Inc. on $80 Million Series C Funding Round

Press Release

Honigman represented Elucid Bioimaging Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, on an $80 million Series C financing round. The round was led by Elevage Medical Technologies, with additional participation from industry strategics and existing investors. With this funding, Elucid is poised to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease. This round brings the company’s total funding to $121 million.

Read the Elucid press release

The Honigman team was led by corporate partners Phil Torrence and John Hertel.

About Honigman

Honigman LLP is an Am Law 200 full-service, general business law firm with more than 350 attorneys in Chicago, Michigan (Ann Arbor, Bloomfield Hills, Detroit, Grand Rapids, Kalamazoo and Lansing), Washington, D.C. and its newest office in Israel (through its wholly owned subsidiary, Honigman Law Israel). Honigman lawyers counsel clients on complex issues in more than 60 areas of law. For more information, visit www.honigman.com.


Related Professionals

Related Services

Media Contact

To request an interview or find a speaker, please contact: press@honigman.com

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.